Summary Monoclonal antibodies reactive with placental-type alkaline phosphatase have formed the basis of methods for detection of this oncodevelopmental antigen in patients with pre-invasive and invasive cervical neoplasia, with or without evidence of papilloma virus infection. Disease-related elevations of placental-type alkaline phosphatase were not observed in patients' sera. Solubilised cervical smears or biopsy material, and cervical mucus swabs, often contained substantial amounts of this isoenzyme; however, there was no significant difference between any of the patient and control groups. Thus, serological and smear test assays for placental-type alkaline phosphatase were not useful in differential diagnosis of cervical lesions. However, its presence in most biopsy specimens, often at high levels, indicated possible application for in vivo radioimmunoimaging studies of invasive or metastatic cervical cancer.
The incidence of cervical cancer has increased markedly in younger women over the last two decades, in part due to venereal transmission of papilloma virus (HPV) infection (Crawford, 1984) . It is not clear whether HPV infection can be a forerunner of cervical intraepithelial neoplasia (CIN), but progression of CIN into overt cancer may be related to concomitant infection by HPV (Syrjanen et al., 1985) . Screening for pre-invasive cervical carcinoma involves exhaustive examination of smears, and therefore simple rapid techniques for identifying pre-invasive cervical neoplasia are attractive to seek.
Potential markers for neoplastic cellular transformation are the oncodevelopmental antigens, such as placental-type alkaline phosphatase. This isoenzyme is a major glycoprotein of term placental trophoblast membranes, and is also expressed on some tumour cell lines including cervical carcinoma cells (McLaughlin et al., 1982) . Two major forms of placental-type alkaline phosphatase have been described, the 'placental' and 'placental-like' alkaline phosphatases (PLAP and PLAP-like AP, respectively). These can be distinguished by relative sensitivity to inhibition by L-leucine (Stigbrand et al., 1982) and differential reactivity with certain monoclonal antibodies (mAbs) (McLaughlin & Johnson, 1984) .
The development of sensitive and specific solid-phase enzyme capture immunoassays (EIA) utilising either the mAb H317 (reactive solely with PLAP) or the mAb H17-E2 (reactive with both PLAP and PLAP-like AP) has broadened investigations of this isoenzyme group in cancer 1984a, b; Epenetos et al., 1985a; Horwich et al., 1985; Tucker et al., 1985) . For example, previous serological assays have been limited by detection of elevated isoenzyme levels in healthy individuals, particularly cigarette smokers (Maslow et al., 1983; Tonik et al., 1983) . It is now clear that this smoking-associated enzyme is PLAPlike AP, rather than PLAP, and thus ig unreactive in the H317-based assay (McLaughlin et al., 1984b Twelve patients from the Oxford region with established cancer of the cervix were also studied. These had squamous carcinoma (n = 9), adenocarcinoma (n =2) or mixed squamous and adenocarcinoma (n= 1); three of the carcinomas were Stage IA, five were Stage IB, three were IIA, and one was IIB.
Monoclonal antibodies (mAbs)
The H317 and H17-E2 hybridomas had been produced following immunisation of mice with isolated human term placental syncytiotrophoblast microvilli (McLaughlin et al., 1982 , Travers & Bodmer, 1984 . The secreted mAbs are both IgGI and were purified from ascitic fluid by affinity chromatography with Sepharose-protein-A (Pharmacia) (Ey et al., 1978) . The H17-E2 mAb reacts with both PLAP and PLAPlike AP, whereas the H317 mAb reacts only with PLAP; neither mAb reacts with non-placental-type alkaline phosphatase isoenzymes (McLaughlin et al., 1982 Travers & Bodmer, 1984) .
Enzyme immunoassays (EIA)
A solid-phase capture assay for PLAP in body fluids, based on the, H317 mAb, has been described in detail 1984b) . The lower limit of detection is less than 0.1 U -1, and none of 120 healthy individuals had serum PLAP levels of >0.1U -1. The H17-E2 mAb has formed the basis of a similar EIA which measures both PLAP and PLAP-like AP . The lower limit of detection is 0.04 U P1 , but occasional healthy individuals and most cigarette smokers have serum levels substantially greater than this and which appears to be PLAP-like AP rather than PLAP (McLaughlin et al., 1984b) .
Solubilised tissue extracts
Cervical biopsy samples (2-15mg wet weight tissue) were suspended in 50vol of PBS with 0.05% Tween 20, pH7.4, and sonicated for a total of 2 min at 4°C. Residual fine particles were allowed to settle for 30 min and the super-natants assayed for placental-type alkaline phosphatases by EIA with a lower limit of detection of 5 U kg-1 tissue.
Cervical smear assay Spatula smear material was solubilised with 2 ml 0.2% sodium deoxycholate in 0.1 M phosphate buffer, pH 8.5. The suspension was centrifuged at 900g for 15min and the supernatant assayed for both protein (Lowry et al., 1951) and placental-type alkaline phosphatases by EIA with a lower limit of detection of 0.5 U g 1 protein.
Cervical swab assay A swab of endocervical mucus was placed in 3ml PBS, pH7.4, and agitated to disperse the mucus. This material was then assayed for placental-type alkaline phosphatases by EIA. Results were expressed as U 1-I.
Cervical mucus samples from normal subjects were collected at a family planning clinic in Sheffield by Dr Nigel Saunders, Department of Obstetrics & Gynaecology, Northern General Hospital, Sheffield.
Results

Serological assay
Circulating H317-reactive PLAP (>0.1 U 11) was not detected in any of 22 CIN patients or 12 patients with established cervical cancer, with or without evidence of HPV infection. However, 12 of these sera did contain H17-E2-reactive PLAP-like AP; this correlated with the expected pattern for smoking-associated circulating PLAP-like AP, since 11 of these 12 patients were cigarette smokers.
Cervical tissue biopsies Of biopsies taken, 31/35 (89%) had detectable placental-type alkaline phosphatase activity in solubilised tissue extracts which was reactive with both H317 and H17-E2 (Figure 1 ). The Hi 7-E2 reactivity was greater than H317 reactivity in most cases, reflecting co-expression of both PLAP and PLAP-like AP. There was no correlation between placentaltype alkaline phosphatase levels and degree of dysplasia or presence of HPV infection of the cervix.
Cervical smears Solubilised smears contained placental-type alkaline phosphatase activity detectable using both H317 and H 17-E2 in 14/29 (48%) cases studied (Figure 2 ). There was reactivity with H17-E2 but not H317 in a further 7 cases (24%), and smears from 8 cases (28%) contained no detectable placental-type alkaline phosphatase reactivity by either assay. There was no difference in distribution of isoenzyme activities between any of the patient groups. Both biopsy material and smears were available from 16 patients. Patients with high tissue biopsy placental-type alkaline phosphatase activities often also had high isoenzymic activity in solubilised smears, although this was not statistically significant by product-moment correlation coefficient analysis.
Cervical swabs
There was a wide range for placental-type alkaline phosphatase activity in swab material (Figure 3 ) similar to that for the smear assay. Over half the samples (51/93, 55%) were reactive in both the H317-based and H17-E2-based assays, and only 29/93 (31%) were negative in both assays. Six of 12 (50%) patients with established cervical cancer had placental-type alkaline phosphatase in cervical mucus detectable with both H3 17 and H 1 7-E2. This was a similar proportion to that found in CIN patients or normal (no CIN) controls (Figure 3) .
The nature of the mucus and its rate of production change around the time of ovulation (Bloom & Fawcett, 1975) , although cervical swab placental-type alkaline phosphatase levels compared at different stages of the menstrual cycle, showed no significant differences. Although circulating H317-reactive PLAP was not detected in this study in pre-invasive or established cervical neoplasia, serum H17-E2-reactive PLAP-like AP was detected in many patients from both groups which correlated better with smoking habits than with cervical disease status. It is of interest that cigarette smoking can lead to an increased risk of cervical cancer (Greenberg et al., 1985) , possibly resulting from local excretion of absorbed carcinogenic products of cigarette smoke (Winkelstein et al., 1984) . However, the original source of the serum PLAP-like AP in these patients is thought most likely to be local release from lung alveolar tissue (Williams et al., 1986) . Cervical biopsy tissue contained both PLAP and PLAPlike AP, as reflected by generally higher isoenzymic activity detected using H17-E2 (reactive with PLAP and PLAP-like AP) than with H317 (reactive with PLAP alone). The levels of activity fell within a wide range, as previously noted for normal cervical tissue (Goldstein et al., 1980; McLaughlin et al., 1984a ), but did not reflect the degree of cellular dysplasia or other cervical pathology. Despite high levels of biopsy PLAP activity in some patients, the isoenzyme was not significantly released intact into the peripheral circulation. Previous studies have also shown that tumour tissue levels of placental-type alkaline phosphatase do not necessarily correlate with circulating levels in ovarian or breast carcinoma (McDicken et al., 1983 (McDicken et al., , 1985 . However, secretion of this isoenzyme into cervical mucus was more evident. Although high levels were often found, these did not correlate with cervical disease status. The precise cellular source of this activity has not been defined but endometrium, endocervical and fallopian tube epithelia are all known to express placental-type alkaline phosphatase (Davies et al., 1985) . We have attempted immunocytology on cervical smears using both H317 and H17-E2 in an indirect immunoperoxidase staining technique; however, no clear differences were noted between normal or abnormal cervix. The high levels of cervical tissue PLAP and PLAP-like AP activities suggest a potential as targets for radioimmunolocalisation of invasive and metastatic disease, as has been performed successfully in ovarian and testicular cancer (Epenetos et al., 1985b; Critchley et al., 1986) , or for determining the extent of lymphatic spread by lymphangiography as has been attempted in cervical cancer using the HMFG2 mAb (Epenetos, 1985) .
There was no significant difference for either PLAP or PLAP-like AP levels between smear, swab or biopsy specimens from HPV-infected compared with HPV-free material. Of 81 patients with CIN, 46% had been designated as having HPV infection of the cervix. This figure, however, is low compared with 70-90% found by McCance et al. (1985) using the more sensitive techniques of DNA hybridisation.
In conclusion, neither circulating nor cervical smear PLAP or PLAP-like AP was found to be a useful parameter of disease status in patients with pre-invasive or established neoplastic lesions of the cervix. Nevertheless, the presence of high levels of PLAP and PLAP-like AP activities within many of these tissues suggests the possibility of effective radioimmunolocalisation of invasive and metastatic disease.
